Quay lại
Giá TransThera Sciences (Nanjing), Inc. (02617.HK)
Biểu đồ giá cổ phiếu 02617.HK
TRANSTHERA-B (02617.HK)
TransThera Sciences (Nanjing), Inc.
HK$95.5
-2.1%
$-2.04
Thị trường đóng cửa: Jan 16, 16:00:00 HKT
Thống kê chính
Giá đóng cửa trước
$95.25
Giá mở cửa
$97.55
Phạm vi ngày
$93.5 - $103.8
Phạm vi 52 tuần
$20.2 - $679.5
Khối lượng
2.5M
Khối lượng trung bình
1.7M
EPS (TTM)
-0.66
Tỷ suất cổ tức
--
Vốn hóa thị trường
$29.1B
TRANSTHERA-B là gì?
TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.
Đặc điểm
Chiến lược giao dịch
Tài nguyên
© 2025 Finture Development Limited. All rights reserved
